TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39315465

Group type: EXPERIMENTAL
Intervention: Innovative Multipoint Impedance-Controlled Radiofrequency Ablation of the Posterior Nasal Nerve
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39315857

Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Number of subjects: 372

Group type: COMPARATOR
Intervention: Vorinostat
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Skindex-29
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: ItchyQol
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: FACT-G
Number of subjects: 372
Study: 39315864

Group type: EXPERIMENTAL
Intervention: BRAF/MEK inhibitors (encorafenib and binimetinib) followed by immune checkpoint inhibitors (ipilimumab and nivolumab)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ipilimumab and nivolumab) followed by BRAF/MEK inhibitors (encorafenib and binimetinib)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: BRAF/MEK inhibitors (encorafenib and binimetinib) for 8 weeks followed by immune checkpoint inhibitors (ipilimumab and nivolumab) and retreatment with BRAF/MEK inhibitors
Number of subjects: 206
Study: 39315892

Group type: EXPERIMENTAL
Intervention: RISA-PE stage A (right ventricular dysfunction and troponin elevation)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: RISA-PE stage B (A + serum lactate >2 mmol/L OR shock index ≥1)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: RISA-PE stage C (persistent hypotension)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: RISA-PE stage D (obstructive shock)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: RISA-PE stage E (cardiac arrest)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: ESC classification for IHR-PE
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: ESC classification for HR-PE
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: RISA-PE classification
Number of subjects: 334
Study: 39315986

Group type: EXPERIMENTAL
Intervention: Mindfulness-based interventions (MBIs) assessed using the Five Factor Mindfulness Questionnaire (FFMQ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39316026

Group type: EXPERIMENTAL
Intervention: Dietary counseling plus omega-3 supplementation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 50
Study: 39316126

Group type: EXPERIMENTAL
Intervention: High training status
Number of subjects: 971

Group type: EXPERIMENTAL
Intervention: Medium training status
Number of subjects: 971

Group type: EXPERIMENTAL
Intervention: Low training status
Number of subjects: 971
Study: 39316164

Group type: EXPERIMENTAL
Intervention: Skin Symptom Assessment (SSA) questionnaire
Number of subjects: 414

Group type: COMPARATOR
Intervention: Radiation-Induced Skin Reaction Assessment Scale (RISRAS) questionnaire
Number of subjects: 414
Study: 39316242

Group type: EXPERIMENTAL
Intervention: Family Check-Up Online (FCU-O)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 161
Study: 39316284

Group type: EXPERIMENTAL
Intervention: CTC 200 mg BID
Number of subjects: 551

Group type: COMPARATOR
Intervention: tramadol 50 mg QID
Number of subjects: 551

Group type: COMPARATOR
Intervention: tramadol 100 mg QID
Number of subjects: 551

Group type: COMPARATOR
Intervention: celecoxib 100 mg BID
Number of subjects: 551

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 551
Study: 39316289

Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 333
Study: 39316288

Group type: EXPERIMENTAL
Intervention: Weight loss interventions from SCALE and STEP 1 studies
Number of subjects: 0
Study: 39316293

Group type: EXPERIMENTAL
Intervention: Macitentan and Tadalafil (M+T)
Number of subjects: 1336
Study: 39316400

Group type: EXPERIMENTAL
Intervention: Voice-activated, internet-delivered cognitive behavioral therapy for insomnia (CBT-I) program for 6 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Educational control for 6 weeks
Number of subjects: 76
Study: 39316536

Group type: EXPERIMENTAL
Intervention: Flower printing activities, 60 min once a week for 1 month
Number of subjects: 42

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 42
Study: 39316653

Group type: EXPERIMENTAL
Intervention: SJ low-risk therapy for NCI high-risk patients with ETV6::RUNX1
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: SJ standard/high-risk therapy for NCI high-risk patients with high-hyperdiploid B-ALL
Number of subjects: 518

Group type: COMPARATOR
Intervention: SJ standard-risk therapy for NCI standard-risk patients with high-hyperdiploid B-ALL
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: SJ low-risk therapy for NCI high-risk patients with high-hyperdiploid B-ALL
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: SJ low-risk therapy
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Contemporary MRD-directed therapy
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Low-intensity regimen for NCI high-risk patients
Number of subjects: 518
Study: 39316666

Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 652

Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 652
Study: 39316768

Group type: EXPERIMENTAL
Intervention: Decitabine and venetoclax (low-dose regimen)
Number of subjects: 0
Study: 39316773

Group type: EXPERIMENTAL
Intervention: Ivacaftor 150mg BID for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ivacaftor
Number of subjects: 40
Study: 39316783

Group type: EXPERIMENTAL
Intervention: MIMIC intervention
Number of subjects: 400
Study: 39316889

Group type: EXPERIMENTAL
Intervention: Low-intensity electrical stimulation (LIES) group
Number of subjects: 38

Group type: COMPARATOR
Intervention: Traditional en-masse retraction (TRAD) group
Number of subjects: 38
Study: 39316931

Group type: EXPERIMENTAL
Intervention: Unmatched cohort (females)
Number of subjects: 9697

Group type: COMPARATOR
Intervention: Unmatched cohort (males)
Number of subjects: 9697

Group type: EXPERIMENTAL
Intervention: Matched cohort (females)
Number of subjects: 9697

Group type: COMPARATOR
Intervention: Matched cohort (males)
Number of subjects: 9697

Group type: EXPERIMENTAL
Intervention: Both cohorts (females and males)
Number of subjects: 9697
Study: 39316947

Group type: EXPERIMENTAL
Intervention: Deviant long tones
Number of subjects: 484

Group type: COMPARATOR
Intervention: Standard pitch tones
Number of subjects: 484
Study: 39317226

Group type: EXPERIMENTAL
Intervention: Proprioceptive vestibular rehabilitation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard vestibular rehabilitation
Number of subjects: 30

Group type: COMPARATOR
Intervention: No exercise (Control group)
Number of subjects: 30
Study: 39317439

Group type: EXPERIMENTAL
Intervention: Vigorous-intensity cycling exercise for 8 weeks
Number of subjects: 14
Study: 39317492

Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: SOC with early high-dose intravenous vitamin C (200 mg/kg per day, within 6 hours after return of spontaneous circulation, for 3 days)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: SOC with early high-dose intravenous vitamin C
Number of subjects: 234
Study: 39317491

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1572

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 1572
Study: 39317507

Group type: EXPERIMENTAL
Intervention: Preoperative stereotactic radiotherapy (12 Gy) to a 4 cm area around the future pancreatic neck transection margin.
Number of subjects: 33
Study: 39317508

Group type: EXPERIMENTAL
Intervention: Focus Group Discussions (FGDs)
Number of subjects: 60
Study: 39317633

Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg and abiraterone acetate 1000 mg plus prednisone 10 mg (AAP)
Number of subjects: 0
Study: 39317830

Group type: EXPERIMENTAL
Intervention: ClearSight monitor
Number of subjects: 30
Study: 39317833

Group type: EXPERIMENTAL
Intervention: Usual-care PR
Number of subjects: 30
Study: 39317994

Group type: EXPERIMENTAL
Intervention: Motor Interference Therapy (MIT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 28
Study: 39318203

Group type: EXPERIMENTAL
Intervention: EuCorVac-19 (ECV-19) vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: COVISHIELD
Number of subjects: 0
Study: 39318387

Group type: EXPERIMENTAL
Intervention: Cabozantinib plus atezolizumab
Number of subjects: 112

Group type: COMPARATOR
Intervention: Single-agent cabozantinib
Number of subjects: 112
Study: 39318595

Group type: EXPERIMENTAL
Intervention: Experimental group (discontinued empirical anti-MRSA therapy if nasal swab result is negative)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (empirical treatment with linezolid or vancomycin)
Number of subjects: 76
Study: 39318593

Group type: EXPERIMENTAL
Intervention: Closed-loop oxygen control
Number of subjects: 33

Group type: COMPARATOR
Intervention: Manual oxygen titrations
Number of subjects: 33
Study: 39318718

Group type: EXPERIMENTAL
Intervention: Health-Related Quality-of-Life Utility Values
Number of subjects: 0
Study: 39318719

Group type: EXPERIMENTAL
Intervention: Microbial inulinase supplementation (2000 inulinase activity units, twice daily for 4 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (twice daily for 4 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Microbial inulinase supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 39318787

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPT)
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Screening and treating only students with detected infections (IST) with hs-RDT
Number of subjects: 746

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 746
Study: 39318788

Group type: EXPERIMENTAL
Intervention: RMC-035 (1.3 or 0.65 mg/kg)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: RMC-035
Number of subjects: 177
Study: 39319046

Group type: EXPERIMENTAL
Intervention: Itepekimab (human monoclonal antibody against IL-33)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39319217

Group type: EXPERIMENTAL
Intervention: Plasma 24-microRNA signature classifier (MSC)
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: MSC+ participants
Number of subjects: 1024
Study: 39319279

Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg/day for patients weighing 10-20 kg (Group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg/day for patients weighing ≥20 kg (Group 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg/day for patients previously diagnosed with GU and/or DU (Group 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg/day for patients previously diagnosed with GU and/or DU (Group 4)
Number of subjects: 0
Study: 39319356

Group type: EXPERIMENTAL
Intervention: Prescription Digital Therapeutic (PDT; Somryst)
Number of subjects: 1565
Study: 39319453

Group type: EXPERIMENTAL
Intervention: Post-PCI stent edge maxLCBI
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Pre-PCI or post-PCI measures of lipid content
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Lipid content in untreated nonobstructive coronary artery lesions
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Residual in-stent or stent edge lipid
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Greater stent edge-related lipid and uncovered plaque burden
Number of subjects: 768
Study: 39319469

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 375

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 375
Study: 39319493

Group type: EXPERIMENTAL
Intervention: Hospitalization for myocardial infarction
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: 12-month follow-up after hospitalization
Number of subjects: 314
Study: 39319513

Group type: EXPERIMENTAL
Intervention: Home-based narrowband UV-B phototherapy
Number of subjects: 783

Group type: COMPARATOR
Intervention: Office-based narrowband UV-B phototherapy
Number of subjects: 783
Study: 39319904

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (Ca(OH)2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Double antibiotic paste (DAP)
Number of subjects: 20
Study: 39320250

Group type: EXPERIMENTAL
Intervention: da Vinci Xi system (DV-RARP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hugo RAS system (H-RARP)
Number of subjects: 100
Study: 39320285

Group type: EXPERIMENTAL
Intervention: High-resolution investigational SCS (HR-SCS)
Number of subjects: 18
Study: 39320397

Group type: EXPERIMENTAL
Intervention: Surgeon behaviors (e.g., establishing rapport, providing reassuring information)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Decision aid arm of Alliance A231701CD
Number of subjects: 30
Study: 39320582

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 1142

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 1142

Group type: EXPERIMENTAL
Intervention: Tofacitinib 2 mg BID
Number of subjects: 1142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1142

Group type: EXPERIMENTAL
Intervention: Tofacitinib (all doses)
Number of subjects: 1142

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 1142
Study: 39320583

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg Q4W
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1002
Study: 39320594

Group type: EXPERIMENTAL
Intervention: Sleep education not supported by social media reminders
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Sleep education supported by social media reminders
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 55
Study: 39320879

Group type: EXPERIMENTAL
Intervention: Fever prevention using an automated surface temperature management device targeting 37.0 °C for 14 days or until ICU discharge.
Number of subjects: 677

Group type: COMPARATOR
Intervention: Standard care with standardized tiered fever treatment on occurrence of temperature of 38 °C or greater.
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Fever prevention group
Number of subjects: 677

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 677
Study: 39320882

Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (CALND)
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Prediction model for high nodal burden
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Prediction model for lobular breast cancer subgroup
Number of subjects: 1010
Study: 39320906

Group type: EXPERIMENTAL
Intervention: Lenvatinib, dosage and duration not specified
Number of subjects: 0
Study: 39320907

Group type: EXPERIMENTAL
Intervention: Crisugabalin 40 mg/d
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Crisugabalin 80 mg/d
Number of subjects: 366

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 366
Study: 39321205

Group type: EXPERIMENTAL
Intervention: Wild-type FA1090 strain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isogenic mutant FA1090 strain (lacking functional MtrCDE pump)
Number of subjects: 0

Group type: COMPARATOR
Intervention: FA19 strain (mutant lacking functional MtrCDE pump)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FA1090 strains in female mice
Number of subjects: 0
Study: 39321347

Group type: EXPERIMENTAL
Intervention: Full-dose dexamethasone (FD-DEX) 40 to 60 mg weekly
Number of subjects: 541

Group type: COMPARATOR
Intervention: Lowered-dose dexamethasone (LD-DEX)
Number of subjects: 541
Study: 39321362

Group type: EXPERIMENTAL
Intervention: Fidanacogene elaparvovec
Number of subjects: 45
Study: 39321363

Group type: EXPERIMENTAL
Intervention: Tulisokibart (1000 mg on day 1 and 500 mg at weeks 2, 6, and 10)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Tulisokibart (for patients with a positive test for likelihood of response)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo (for patients with a positive test for likelihood of response)
Number of subjects: 135
Study: 39321361

Group type: EXPERIMENTAL
Intervention: Ziresovir (10 to 40 mg, according to body weight), administered twice daily for 5 days
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo, administered twice daily for 5 days
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Ziresovir
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 39321425

Group type: EXPERIMENTAL
Intervention: Transient or low-titer aPLs
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Antiphospholipid syndrome (APS)
Number of subjects: 524
Study: 39321453

Group type: EXPERIMENTAL
Intervention: Web-based weekly survey for out-of-pocket costs
Number of subjects: 13
Study: 39321757

Group type: EXPERIMENTAL
Intervention: Integrated Stepped Alcohol Treatment with Contingency Management (ISAT + CM)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 120
Study: 39322114

Group type: EXPERIMENTAL
Intervention: Medically supportive food and behavioral lifestyle program
Number of subjects: 355

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 355
Study: 39322173

Group type: EXPERIMENTAL
Intervention: Presence of cardiovascular risk factors and high burden of subclinical atherosclerosis
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Cerebrovascular pathology and intracranial atherosclerosis
Number of subjects: 1000
Study: 39322237

Group type: EXPERIMENTAL
Intervention: PROVIDE model (n=187) - integrated mental health video consultation approach with five real-time video sessions
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: PROVIDE model (n=187) - integrated mental health video consultation approach
Number of subjects: 376

Group type: COMPARATOR
Intervention: Usual care (n=189) - provided by GPs through brief counselling and psychotropic medication prescriptions
Number of subjects: 376
Study: 39322365

Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid valve intervention (TTVI)
Number of subjects: 483
Study: 39322513

Group type: EXPERIMENTAL
Intervention: Plaque rupture
Number of subjects: 232
Study: 39322524

Group type: EXPERIMENTAL
Intervention: Olpasiran in addition to standard-of-care
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Pelacarsen in addition to standard-of-care
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Olpasiran and pelacarsen
Number of subjects: 2
Study: 39322526

Group type: EXPERIMENTAL
Intervention: High remnant cholesterol (> 20.5 mg/dL; n = 1,116)
Number of subjects: 3348

Group type: EXPERIMENTAL
Intervention: Intermediate remnant cholesterol (14‒20.5 mg/dL; n = 1,031)
Number of subjects: 3348

Group type: EXPERIMENTAL
Intervention: Low remnant cholesterol (≤14.0 mg/dL; n = 1,201)
Number of subjects: 3348

Group type: EXPERIMENTAL
Intervention: On-treatment remnant-C cut-off of 17 mg/dL (median)
Number of subjects: 3348

Group type: EXPERIMENTAL
Intervention: Achieving LDL-C <55 or 70 mg/dL
Number of subjects: 3348
Study: 39322590

Group type: EXPERIMENTAL
Intervention: Delphi consensus exercise
Number of subjects: 15
Study: 39322600

Group type: EXPERIMENTAL
Intervention: Incident pregnancy over 1 year
Number of subjects: 2015

Group type: COMPARATOR
Intervention: Comparison participants (non-pregnant)
Number of subjects: 2015
Study: 39322611

Group type: EXPERIMENTAL
Intervention: dostarlimab+carboplatin-paclitaxel
Number of subjects: 118
Study: 39322711

Group type: EXPERIMENTAL
Intervention: Epcoritamab
Number of subjects: 0
Study: 39322802

Group type: EXPERIMENTAL
Intervention: CT-P17 (100 mg/mL), citrate-free adalimumab biosimilar
Number of subjects: 232

Group type: COMPARATOR
Intervention: R-ADA (100 mg/mL)
Number of subjects: 232

Group type: COMPARATOR
Intervention: ADA-BioS (50 mg/mL)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Previous treatment with ADA-BioS
Number of subjects: 232

Group type: COMPARATOR
Intervention: Previous treatment with pain at injection site
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: CT-P17 treatment
Number of subjects: 232
Study: 39322817

Group type: EXPERIMENTAL
Intervention: Physiotherapy on the 1st, 7th, and 30th postoperative days; surgical wound care by nurses on the 7th, 14th, and 21st postoperative days.
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Overweight or obese status
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Axillary lymphadenectomy
Number of subjects: 249
Study: 39322961

Group type: EXPERIMENTAL
Intervention: Erenumab (70 mg or 140 mg) for migraine prophylaxis over 128 weeks.
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Erenumab treatment after drug holiday.
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Drug holiday (voluntary treatment interruption of up to 24 weeks).
Number of subjects: 701
Study: 39323188

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 407
Study: 39323258

Group type: EXPERIMENTAL
Intervention: Post-operative thoracic epidural analgesia
Number of subjects: 66

Group type: COMPARATOR
Intervention: Oral morphine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Post-operative pain management (both groups)
Number of subjects: 66
Study: 39323439

Group type: EXPERIMENTAL
Intervention: Self-reported non-smoking status with eCO concentration <6 ppm
Number of subjects: 1291

Group type: COMPARATOR
Intervention: Self-reported smoking status with eCO concentration <6 ppm
Number of subjects: 1291

Group type: EXPERIMENTAL
Intervention: Elevated eCO concentration (≥6 ppm)
Number of subjects: 1291
Study: 39323753

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffolds (BVSs)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Everolimus-eluting stents (DES)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stents (BESs)
Number of subjects: 240
Study: 39323780

Group type: EXPERIMENTAL
Intervention: Orthokeratology (OK) lenses
Number of subjects: 300

Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 300
Study: 39324115

Group type: EXPERIMENTAL
Intervention: Initial Takotsubo syndrome (TTS) event
Number of subjects: 88
Study: 39324520

Group type: EXPERIMENTAL
Intervention: Self-reported hearing loss in CN participants
Number of subjects: 1636

Group type: EXPERIMENTAL
Intervention: Self-reported hearing loss in CN and MCI participants
Number of subjects: 1636
Study: 39324668

Group type: EXPERIMENTAL
Intervention: Dual-target HCC blood test (DT-HBT)
Number of subjects: 1030